Factors influencing post-transfusional platelet increment in pediatric patients given hematopoietic stem cell transplantation

被引:0
作者
CL Balduini
L Salvaneschi
C Klersy
P Noris
M Mazzucco
F Rizzuto
G Giorgiani
C Perotti
P Stroppa
MDi Pumpo
B Nobili
F Locatelli
机构
[1] IRCCS San Matteo–University of Pavia,Department of Internal Medicine
[2] Blood Transfusion Centre,Department of Pediatrics
[3] IRCCS San Matteo,Department of Pediatrics
[4] Biometry and Clinical Epidemiology,undefined
[5] IRCCS Policlinico San Matteo,undefined
[6] IRCCS San Matteo–University of Pavia,undefined
[7] Ospedale I Policlinico–II University of Naples,undefined
来源
Leukemia | 2001年 / 15卷
关键词
bone marrow transplantation; platelet transfusion; human platelet antigens; alloantibodies;
D O I
暂无
中图分类号
学科分类号
摘要
Patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT) always require platelet transfusions, but the increase in platelet count is often less than expected. Since factors responsible for poor response to platelet transfusions in this clinical setting are largely unknown, we performed a prospective study in 87 consecutive children transplanted in a single institution. The mean 16-h corrected count increment (CCI) of 598 platelet transfusions was 5.76 ± 8.32 × 109/l. Both before and after HSCT, 13.8% of patients had antibodies against HLA and/or platelet-specific antigens. Univariate analysis identified 12 factors significantly associated with a lower post-transfusion CCI, but only four reached statistical significance in the multivariate analysis. These four factors were concomitant therapy with vancomycin, alloimmunization, use of an Autopheresis cell separator for preparation of platelet concentrates and cytomegalovirus infection. We, therefore, suggest that a better response to platelet transfusions could be obtained by choosing a suitable cell separator, by avoiding the use of vancomycin and by adopting measures that reduce alloimmunization and CMV infection. Moreover, screening patients for HLA and platelet-specific antibodies before HSCT would identify the majority of subjects who will develop alloimmune refractoriness after transplantation and would allow the search for a compatible donor in advance.
引用
收藏
页码:1885 / 1891
页数:6
相关论文
共 173 条
  • [1] Meehan KR(2000)Platelet transfusions: utilization and associated costs in a tertiary care hospital Am J Hematol 64 251-256
  • [2] Matias CO(1994)The efficacy of leukodepletion to improve platelet transfusion response: a critical appraisal of clinical studies Transfus Med Rev 8 15-28
  • [3] Rathore SS(1997)Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusion N Engl J Med 337 1861-1869
  • [4] Sandler SG(1998)Clinical factors influencing posttransfusion platelet increment in patients undergoing hematopoietic progenitor cell transplantation – a prospective analysis Transfusion 38 839-847
  • [5] Kallich J(1995)Causes of refractoriness to platelet transfusion Curr Opin Hematol 2 493-498
  • [6] LaBrecque J(1996)Factors associated with response to platelet transfusion following hematopoietic stem cell transplantation Bone Marrow Transplant 17 1035-1041
  • [7] Erder H(2000)Bleeding risk and platelet transfusion refractoriness in patients with acute myelogenous leukemia who undergo autologous stem cell transplantation Bone Marrow Transplant 26 315-320
  • [8] Schulman KA(1988)Clinical factors influencing the efficacy of pooled platelet transfusions Blood 71 383-387
  • [9] Heddle NM(1996)Clinical and laboratory factors associated with platelet transfusion refractoriness: a case-control study Br J Haematol 93 220-224
  • [10] The Trial to Reduce Alloimmunization to Platelets Study Group(1996)Influence of antibiotics on posttransfusion platelet increment Transfusion 36 952-954